MGNX
Companies
NASDAQ
Macrogenics Inc.
Health Care
$1.37
-$1.94 (-59.54%)
Price Chart
Overview
About MGNX
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).
Market Cap
$283.7M
Volume
1.5M
Avg. Volume
979.2K
P/E Ratio
-0.42946056
Dividend Yield
0.00%
Employees
377.0
Company Information
Risk & Correlation Analysis
Market Correlation
2.06
High Correlation
Volatility
High (0.88)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, MGNX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$283.7M
Volume1.5M
P/E Ratio-0.43
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 21, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025